Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Earnings Roundup: Eisai's Accelerated Perampanel Development Hits The Brakes; Takeda Averts Actos Setbacks For Now

This article was originally published in PharmAsia News

Executive Summary

TOKYO - A busy Friday of quarterly earnings presentations gave a first glimpse of the full impact of the March 11 earthquake and tsunami in Northern Japan. Takeda Pharmaceutical Co. Ltd., Otsuka Holdings Co., Ltd., Daiichi Sankyo Co. Ltd, Mitsubishi Tanabe Pharma Corp. and Dainippon Sumitomo Pharma Co. Ltd. all reported July 29 earnings for the first full quarter since the earthquake, but perhaps the biggest news of the day was an announcement from Eisai Co. Ltd. on a setback to what had been an ambitious drive for a key drug's approval
Advertisement

Related Content

Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk
Mitsubishi Tanabe's Key Products And M&A Rumors Tempered By Management Issues
Advertisement
UsernamePublicRestriction

Register

SC078619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel